drugset / Trial / NCT01165320

A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)

NCT01165320

Phase 2 Completed 20 enrolled Merck Sharp & Dohme LLC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study estimates the safety, efficacy, and pharmacokinetics of caspofungin (MK-0991) in Japanese children and adolescents with documented Candida or Aspergillus infections.

Timeline

Start
2010-07-06
Primary completion
2013-09-17
Completion
2013-09-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Caspofungin Other / unclassified 50 mg/m2 Intravenous